Clinical Trials on Prostatic Neoplasms, Castration-Resistant in United States

Total 3726 results

Nuvation Bio Inc.

Withdrawn

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Prostate Cancer | Prostate Neoplasm | Cancer of the Prostate | Prostatic Cancer | Castrate Resistant Prostate Cancer | Cancer of Prostate | Castration Resistant Prostatic Cancer | Castration Resistant Prostatic Neoplasms

United States
Janux Therapeutics

Recruiting

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic Cancer

United States, Australia
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

Metastatic Prostate Cancer | Castration Resistant Prostatic Cancer

United States
BAMF Health

Recruiting

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study) (SPECTacular)

Metastatic Castration-resistant Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Clarus Therapeutics

Recruiting

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Massachusetts General Hospital
Bayer

Completed

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to Bone

United States
MANA RBM
Bayer; Tulane University; Barbara Ann Karmanos Cancer Institute; Carolina Urologic...

Terminated

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients (ESCALATE)

Metastatic Castration-resistant Prostate Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (FASN)

Prostate Cancer | Refractory Cancer | Castration Resistant Prostatic Cancer

United States
Myovant Sciences GmbH

Recruiting

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate Cancer

United States
Rohan Garje
Janssen Scientific Affairs, LLC

Not yet recruiting

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer (LUNAAR)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Dana-Farber Cancer Institute
Progenics Pharmaceuticals, Inc.

Not yet recruiting

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate Carcinoma

United States
Veru Inc.

Terminated

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent (VERACITY)

Metastatic Castration-resistant Prostate Cancer | Androgen Resistant Prostatic Cancer

United States
Janssen Research & Development, LLC

Completed

A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostatic Neoplasms

Canada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
Celcuity Inc

Recruiting

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | Genital Diseases, Male | Prostatic Disease | mCRPC (Metastatic Castration-resistant Prostate Cancer) | Urogenital Diseases, Male

United States, France, Spain, United Kingdom
Vadim S Koshkin
Eli Lilly and Company; Prostate Cancer Foundation

Active, not recruiting

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer (UPLIFT)

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate Carcinoma

United States
Donald Trump, MD

Terminated

Oral Calcitriol With Ketoconazole in CRPC

Castration-resistant Prostate Cancer

United States
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)

Prostatic Neoplasms, Castration-Resistant | Prostatic Cancer, Castration-Resistant | Castration Resistant Prostatic Neoplasms | Androgen-Resistant Prostatic Neoplasms

United States, Canada
Io Therapeutics

Completed

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

Castration Resistant Prostate Cancer

United States
Tulane University
Blue Earth Diagnostics

Completed

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

Metastatic Castration-resistant Prostate Cancer

United States
Terence Friedlander, MD
Janssen Biotech, Inc.

Completed

A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer

Castration Resistant Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

Metastatic Castration-Resistant Prostate Cancer

United States
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

Metastatic Castration-Resistant Prostate Cancer

United States
Endocyte

Terminated

Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy (RESIST-PC)

Metastatic Castration Resistant Prostate Cancer

United States
Pellficure Pharmaceuticals, Inc

Terminated

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States
Bayer

Completed

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). (PHENIX)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

United States
Memorial Sloan Kettering Cancer Center
Celgene Corporation

Completed

Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer

Prostate Cancer | Castration Resistant Prostate Cancer

United States
Asana BioSciences

Terminated

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Prostate Neoplasms, Castration-resistant

United States
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

Metastatic Progressive Castration-resistant Prostate Cancer

United States
Jodi Layton, MD
EMD Serono

Terminated

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Metastatic Castration-resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Prostate Neoplasms | Metastatic Castration Resistant Prostate Cancer

United States
Duke University
Bayer

Completed

Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer

Bone Metastatic Castration-Resistant Prostate Cancer

United States
Merus N.V.

Recruiting

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Metastatic Castration-resistant Prostate Cancer | NSCLC Harboring NRG1 Fusion

United States
Northwestern University

Recruiting

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Refractory Prostate Cancer | Castration-Resistant Prostatic Cancer

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer

Castration-resistant Prostate Cancer | Stage IV Prostate Cancer

Singapore, United States
University of California, San Francisco
Merck Sharp & Dohme LLC; Prostate Cancer Foundation

Recruiting

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Prostate Cancer | Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer

United States
Lava Therapeutics

Recruiting

Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer

United States
UNC Lineberger Comprehensive Cancer Center

Withdrawn

Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
Memorial Sloan Kettering Cancer Center
Progenics Pharmaceuticals, Inc.

Completed

Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Opna-IO LLC

Terminated

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

United States, United Kingdom
Bayer

Completed

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo) (EPIX)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
MedImmune LLC

Completed

A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer (MEDI3726)

Metastatic Castration Resistant Prostate Cancer

United States, Switzerland, United Kingdom
University of Alabama at Birmingham
Amgen

Completed

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

Metastatic Castration-resistant Prostate Cancer

United States
Rahul Aggarwal
Sanofi

Completed

Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States
Dana-Farber Cancer Institute
Medivation, Inc.

Completed

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States
Dana-Farber Cancer Institute
Pfizer; Astellas Pharma Inc

Completed

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Castration-resistant Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Withdrawn

A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer (Radium-223)

Prostate Cancer | Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)

United States
Zenith Epigenetics

Completed

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Progenics Pharmaceuticals, Inc.

Not yet recruiting

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

Prostate Adenocarcinoma | Castration Resistant Prostate Cancer | Castration Sensitive Prostate Cancer

United States
FutureChem

Recruiting

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application (LUCIDA)

Metastatic Castration-resistant Prostate Cancer

United States
Dizal Pharmaceuticals

Terminated

Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC

Metastatic Castration Resistant Prostate Cancer

United States, Korea, Republic of

Clinical Trials on Prostatic Neoplasms, Castration-Resistant in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations